Stockreport

Exact Sciences gains 6% following data on blood-based colorectal cancer test [Seeking Alpha]

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF Data showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonosco [Read more]